6-氧代-1-氮杂螺[3.3]庚烷-1-羧酸叔丁酯 | 1363380-93-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 6-氧代-1-氮杂螺[3.3]庚烷-1-羧酸叔丁酯
• 中文别名: 6-氧代-1-氮杂萘并[3.3]庚烷-1-羧酸叔丁酯
• 英文名称: tert-butyl 6-oxo-1-azaspiro[3.3]heptane-1-carboxylate
• CAS: 1363380-93-1
• 化学式: C₁₁H₁₇NO₃
• 分子量: 211.261
• InChiKey: YQTHBUWNYDZION-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319

反应信息

• 作为反应物：
  描述：

  6-氧代-1-氮杂螺[3.3]庚烷-1-羧酸叔丁酯 在 sodium hydride 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 0.75h， 生成
  参考文献：
  名称：

  Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model

  摘要：

  Allogeneic hematopoietic cell transplantation (allo-HCT) is a highly effective, well-established treatment for patients with various hematologic malignancies and non-malignant diseases. The therapeutic benefits of allo-HCT are mediated by alloreactive T cells in donor grafts. However, there is a significant risk of graft-versus-host disease (GvHD), in which the donor T cells recognize recipient cells as foreign and attack healthy organs in addition to malignancies. We previously demonstrated that targeting JAK1/JAK2, mediators of interferon-gamma receptor (IFNGR) and IL-6 receptor signaling, in donor T cells using baricitinib and ruxolitinib results in a significant reduction in GvHD after allo-HCT. Furthermore, we showed that balanced inhibition of JAK1/JAK2 while sparing JAK3 is important for the optimal prevention of GvHD. Thus, we have generated novel JAK1/JAK2 inhibitors, termed WU derivatives, by modifying baricitinib. Our results show that WU derivatives have the potential to mitigate GvHD by upregulating regulatory T cells and immune reconstitution while reducing the frequencies of antigen-presenting cells (APCs) and CD80 expression on these APCs in our preclinical mouse model of allo-HCT. In addition, WU derivatives effectively downregulated CXCR3 and T-bet in primary murine T cells. In summary, we have generated novel JAK inhibitors that could serve as alternatives to baricitinib or ruxolitinib.

  DOI：

  10.3390/molecules29081801
• 作为产物：
  描述：

  叔丁基6-羟基-1-氮杂螺[3.3]庚烷-1-羧酸酯 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 以85 %的产率得到6-氧代-1-氮杂螺[3.3]庚烷-1-羧酸叔丁酯
  参考文献：
  名称：

  1-氮杂螺[3.3]庚烷作为哌啶的生物等排体**

  摘要：

  合成、表征并验证了 1-氮杂螺[3.3]庚烷作为哌啶的生物等排体。将这个核心代替哌啶环掺入麻醉药物布比卡因中，产生了具有高活性的无专利类似物。

  DOI：

  10.1002/anie.202311583

文献信息

• [EN] AMINO-PYRIMIDINE AMIDES<br/>[FR] AMIDES D'AMINO-PYRIMIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2021249908A3

  公开（公告）日：2022-02-24